



Discovery and Development of Novel Therapeutic Agents in Infectious Diseases Treatment

Guest Editors:

Dr. Tinchun Chu

Department of Biological
Sciences, Seton Hall University,
South Orange, NJ, USA

Dr. Lee H. Lee

Department of Biology, Montclair
State University, Montclair, NJ,
USA

Deadline for manuscript
submissions:

closed (1 August 2023)

Message from the Guest Editors

Dear Colleagues,

Infectious diseases refer to infections caused by pathogenic microorganisms, including bacteria, viruses, fungi, and helminths. For the past few decades, many epidemic or pandemic outbreaks of emerging and re-emerging diseases have caused significant morbidity and mortality. Despite medical advances with new treatments and better access to healthcare, multidrug resistance problems, including antibiotic resistance, and the discovery of new therapeutic agents for emerging diseases remain a major challenge and burden in healthcare. Thus, developing safe and effective therapeutic agents is urgently needed in this new era of infectious diseases.

We would like to invite researchers to contribute articles, either original research articles or reviews, on modern approaches to focus on the discovery and development of new anti-infectious agents. The candidates of these agents can be small molecules, natural products, or modified natural products. Furthermore, the studies can include but are not limited to antimicrobial agents' discovery, efficacy, safety, mechanisms, and therapeutic approaches to establish strategies to combat infectious diseases.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi